Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia
Citations Over TimeTop 10% of 2006 papers
Abstract
Intravenous immunoglobulin (IVIG) is currently used to treat a multitude of autoimmune disorders including immune thrombocytopenic purpura (ITP), yet the mechanism of action of IVIG remains unresolved. Using a murine model of ITP in which IVIG functions therapeutically, our laboratory has addressed such theories as blockade/inhibition of the mononuclear phagocytic system, cytokine regulation, and neutralization of pathogenic autoantibodies mediated by anti-idiotypic antibodies, and these findings will be discussed herein. We have also demonstrated that soluble immune complexes can completely recapitulate the therapeutic effects of IVIG in ITP, and recent work from us has identified activating Fcgamma receptors on CD11c+ dendritic cells as the relevant molecular target of IVIG in the acute resolution of murine immune thrombocytopenia. This and other work to devise antibody-based IVIG alternative therapies will also be addressed.
Related Papers
- → Autoantibodies, detection methods and panels for diagnosis of Sjögren's syndrome(2017)63 cited
- → The significance of preclinical anti-BP180 autoantibodies(2022)12 cited
- → Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65(2005)30 cited
- → Occurence of autoantibodies in healthy Omani individuals(2001)5 cited
- Analysis of autoantibodies in 83 patients with primary hepatic carcinnoma(2010)